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a  b  s  t  r  a  c  t
CD4pos T-cell  subsets  play  a  role  in  myelodysplastic  syndromes  (MDS)  pathogenesis  and  may  be affected
upon  5-azacitidine  (Aza)  treatment.  Aza  enhanced  human  TH1 frequencies  in vitro but  not  in  vivo.  The
proportion  of functional  FoxP3pos regulatory  T cells  (Treg)  was  enhanced  by Aza in vitro  (p  < 0.0002),  and
a  modest,  temporary  increase  was  observed  in  vivo  (p  =  0.08).  The  overall  number  of  TH17  was  reduced
both  in  vitro  (p  <  0.03)  and  in vivo (p  <  0.006),  indicating  that  Aza  directly  affects  CD4pos polarization  during
activation  in  vitro. Upon  in  vivo treatment  in high  risk  MDS  patients,  particularly  the  T 17-Treg  axis  iseywords:
zacitidine
ytokines
egulatory T-cells
L-17
D4 T-helper cells
H
affected.
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. Introduction
Demethylating agents such as the DNA methyltransferase
DNMT) inhibitor 5-azacitidine (Aza) are increasingly used for the
reatment of myelodysplastic syndromes (MDS), acute myeloid
eukemia (AML) and multiple myeloma (MM)  [1–4]. Treatment
ith Aza was shown to increase overall survival in high risk MDS
atients as compared to conventional care [5].  The mechanisms
ehind the therapeutic effects of Aza are not yet clear, differentia-
ion induction, direct cytotoxic effects on dysplastic clones as well
s enhanced expression of tumor-associated antigens (TAA), which
re targets for the immune response are likely to contribute to the
utcome of treatment [6–8].
Immune editing is recognized as being important in the patho-
enesis of MDS  [9].  Over-production of pro-inﬂammatory cytokines
uch as TNF and to a lesser extend IFN appears to acceler-
te apoptosis of haematopoietic progenitors in the bone marrow
nd thus contribute to the disturbed haematopoiesis in low-risk
DS  [10,11].  The role of IL-17 is less clear. Increased frequen-
ies of IL-17 producing CD4pos TH17 cells have been observed in
eripheral blood of low risk patients suggesting a role for increased
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Open access under the Elsevier OA license. autoimmunity in low risk MDS  and a possible role in an effective
immune response against the dysplastic clone [12]. On the other
hand in the bone marrow of early MDS  cases TH17 frequencies were
reduced and produced less IL-21 and IL-22, as compared to late MDS
cases [13]. In addition to abnormal production of inﬂammatory
cytokines immune evasion characterized by increased numbers of
FoxP3pos Treg may  be related to the outgrowth of (transformed)
blasts in high risk MDS  cases [13,14].
Next to direct effects of Aza on dysplastic and/or tumor cells,
modulation of lymphocyte effector functions are likely to occur,
as both cytokine production and FoxP3 expression by T-cells have
been shown to be epigenetically regulated in vitro [15,16]. The
promoter of FoxP3, a key gene for the function of CD25hi regula-
tory T-cells (Treg), is methylated in conventional CD4posCD25neg
T-cells [17]. It has been demonstrated previously that treatment
with DNMT inhibitors induces conversion of human CD4posCD25neg
conventional T-cells into CD25posFoxP3pos cells with regulatory
function [15]. Recent studies in transplantation models suggest that
Aza may  be an effective treatment for graft versus host disease par-
ticular due to its combined effects on TAA expression and FoxP3
expression [18,19].
However, effects of Aza treatment on (inﬂammatory) cytokine
production are less clear; conﬂicting results regarding IFN pro-
duction upon treatment with demethylating agents have been
reported [16,18,20,21] while epigenetic control of TNF and IL-17
production, both of which are related to the increased bone mar-
row apoptosis in low risk MDS, have been less extensively studied
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Table 1
Patient’s characteristics.
Ptnt# Age FAB WHO  2008 Response T-cell monitoring Time in FU
1 69 RAEB-t AML  with multilineage dysplasia Responder T = 0, 15 days, 3 cycles 9 cycles, pause due to toxicity
2 74 RAEB  RAEB-2 Stable T = 0, 15 days, 3 cycles 12 cycles, ongoing
3 67  RAEB RAEB-2 Progression T = 0, 15 days 6 cycles, progressive disease
4  71 RAEB RAEB-2 Responder T = 0, 15 days 9 cycles, ongoing
5a 74 RAEB RAEB-2 Progression T = 0, 15 days Died of disease after 2 cycles
6  72 RAEB-t AML  with multilineage dysplasia Progression T = 0, 15 days, 3 cycles Died of disease after 3 cycles
7  66 CMML  CMML-1 Stable T = 0, 15 days, 3 cycles 3 cycles, pause due to toxicity
8 74 RAEB RAEB-2 Progression T  = 0, 15 days, 3 cycles 3 cycles, progressive disease
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Treg.9 72 CMML  CMML-2 
a No cytokines measured due to a technical error.
10,12,21].  Furthermore, in vivo effects of Aza on Treg development
nd cytokine production in humans have not yet been reported.
We  therefore set out to investigate the effects of Aza treat-
ent on CD4pos T-cell subset frequencies in vivo, in high-risk MDS
atients. In addition the effect of Aza treatment on the conversion
f conventional CD4pos T-cells into FoxP3 expressing Treg, as well
s on the frequency of IFN, TNF and IL-17 producing T-cells was
nalyzed in healthy donors in vitro.
. Materials and methods
.1. Study design and patients
Patients with intermediate-2 and high risk MDS  (n = 9, IPSS score ≥ 1.5), CMML
nd AML with 20–30% blasts and multilineage dysplasia were included in this study.
he study received local institutional review board approval. Patients received s.c.
njections of 75 mg/m2/day Aza on the ﬁrst 7 days of a 28 day cycle. After informed
onsent, blood was  drawn from 3 patients at the start of Aza treatment and at day
5  of cycle 1. Of an additional 6 patients blood was  drawn after 3 completed cycles
s  well. Table 1 shows the characteristics of the patients.
.2. Isolation of PBMC and T-cell subsets
Peripheral blood was  acquired after informed consent from healthy blood
onors and MDS  patients. PBMC were isolated within 24 h of blood sampling using
coll density-gradient centrifugation (Ficoll-Paque, Amersham Pharmacia Biotech,
ppsala, Sweden). For the in vitro assays, CD4pos T-cells were subsequently isolated
y  MACS sorting using the CD4 positive isolation kit from Miltenyi Biotec (Bergisch
ladbach, Germany). CD4pos cells were subsequently stained with CD25-PE (BD Bio-
ciences, San Jose, CA, USA) and sorted into CD25neg and CD25dim subsets by sorting
sing a FACSaria ﬂow cytometer (BD Biosciences, San Jose, CA) with a purity of
ypically >95%.
.3. In vitro stimulation of isolated CD4pos subsets
20 × 106/ml  CD4pos T-cells (total, CD25neg or CD25dim) were labeled with CFSE
Molecular probes, Eugene, OR; 3 M in PBS) for 10 min  at 37 ◦C followed by 2 min
ncubation at room temperature upon addition of an equal volume of fetal calf
erum (FCS, Greiner Bio-one, Alphen aan de Rijn, The Netherlands). After washing
he  cells were resuspended in IMDM culture medium supplemented with 0.01 mM
-mercaptoethanol and 50 units/ml penicillin-streptomycin (all from Gibco, Pais-
ey, UK) and 5% FCS (10 × 106/ml). CD3 (4 g/ml; Sanquin Reagents, Amsterdam, The
etherlands) labeling was subsequently performed during 1 h on ice. After wash-
ng the cells were resuspended to 4 × 105/ml IMDM/10% FCS and 500 l/well was
lated out on goat-anti-mouse IgG coated (DakoCytomation, Glostrup, Denmark) 48
ell  plates. Aza (Sigma–Aldrich, Saint Louis, MO)  was  dissolved in acetic acid (VWR,
ontenay-sous-Bois, France; 50% (v/v) in H2O) to a concentration of 20 mM and used
t  10 nM–10 M.  Freshly dissolved and diluted Aza or an equal volume of vehicle
as  added on day 1, 2 and 3, on day 6 the cells were harvested and CFSE dilution
as  determined by ﬂow cytometry and the proliferation index was calculated by
odFit software.
.4. Treg and cytokine production analysis
Peripheral blood T-cell subset frequencies in MDS  patients were analyzed using
ix-color ﬂow cytometry. FITC, PE, PerCP, APC, PE-Cy7 or APC-H7 conjugated mono-
lonal antibodies directed against the following markers were applied: CD45, CD3,
D4,  CD8, CD127, IL-4, IFN, (all BD Biosciences), FoxP3 (e-Bioscience, San Diego,
A,  USA), IL-17A and TNF (Biolegend, San Diego, CA, USA). Data obtained from
 minimum of 20,000 CD4pos cells acquired by a FACS Canto II ﬂow cytometer
sing FACSDiva software were analyzed using CellQuestPro software. Absolute lym-
hocyte subset numbers were calculated as follows; absolute number of CD3posrogression T = 0, 15 days, 3 cycles 3 cycles, progressive disease
T-cells: lymphocyte count × (%CD3 in lymphocyte gate/100) and absolute number
of  CD3posCD4pos T-cells: absolute CD3pos T-cell count × (%CD4pos cells within CD3pos
lymphocyte gate/100). Results are shown as percentage of CD3posCD4pos T-cells.
Treg cells were identiﬁed as CD3posCD4posCD127lo/negFoxP3pos (example of gating
procedure is shown in Supplementary Fig. 1A). Intracellular FoxP3 staining was
performed according to the manufacturer’s instructions. Cytokine producing cells
were identiﬁed after 16 h stimulation with phorbol 12-myristate 13-acetate (PMA,
2.5 ng/ml) and ionomycin (1 g/ml), 10 g/ml Brefeldin A was added after 1 h (all
from Sigma–Aldrich). After surface staining with CD45, CD3 and CD8, the cells were
ﬁxed (1% (v/v) paraformaldehyde, Sigma–Aldrich) and permeabilized (0.1% saponin,
Merck, Darmstadt, Germany) and antibodies against IL-17A, TNF and IL-4 and IFN
were added. CD4pos T-cells were deﬁned as CD3posCD8neg (example of gating pro-
cedure is shown in Supplementary Fig. 1B), as cell surface expression of CD4 is
signiﬁcantly reduced after PMA/ionomycin stimulation, this population therefore
includes double negative T-cells.
The in vitro stimulated healthy donor derived CD4pos T-cells were analyzed sim-
ilarly. However, Treg were deﬁned as CD25hiFoxP3pos using CD25-PE and FoxP3-APC
antibodies. After 6 days culture the cells were harvested and Treg frequencies were
directly determined. The remaining cells were stimulated with PMA/ionomycin as
described above. Upon ﬁxation and permeabilization cells were stained with anti-
bodies against IL-17A and TNF combined with antibodies against IFN or FoxP3.
Data were obtained from a minimum of 20,000 CD4pos cells in the live gate using the
FACS Canto and FACSDiva software and were subsequently analyzed using CellQuest
software (BD Biosciences).
2.5. Real time quantitative reverse transcriptase PCR
Cells were harvested and snap-frozen on day 6. RNA was isolated and
reverse transcribed into cDNA as described previously [22]. Transcripts were
quantiﬁed by real-time quantitative polymerase chain reaction on a ABI/PRISM
7500 sequence detection system using pre-designed TaqMan GeneExpression
Assays and reagents according to the manufacturer’s instructions (Applied Biosys-
tems, Foster City, CA). Probes with the following Applied Biosystems assay
identiﬁcation numbers were used: TBX21, Hs00203436 m1  (Tbet); RORC vari-
ant 1 and 2, Hs01076112 m1  (RoRT) and FOXP3, Hs00203958 m1. Data were
normalized using the human HPRT1 Endogenous Control (4333768T, Applied
Biosystems).
2.6. Treg assay
After 6 days of culture in the presence of vehicle or Aza healthy donor derived
CD4pos T-cells were harvested and stained with CD25-PE and sorted into CD25hi
and CD25dim/neg cells, in order to enrich for FoxP3pos cells in the CD25hi popu-
lation. These sorted cells as well as untreated CD4posCD25neg cells were labeled
with PKH26 (2 l/ml; Sigma–Aldrich) in PBS (1 × 106 cells/ml) for 10 min  at room
temperature. An equal volume of FCS was added and after additional 2 min incu-
bation the cells were washed and resuspended in IMDM/10%FCS. Autologous total
CD4pos T-cells were labeled with CFSE and anti-CD3 as described above (“Tresp”),
washed and resuspended in IMDM/10%FCS and plated out at 50,000 cells per well
on  a goat-anti-mouse coated ﬂat-bottomed well plate. 1 × 105 or 50,000 PKH62
labeled untreated, vehicle or Aza cultured CD25neg or vehicle or Aza cultured CD25hi
(“Treg”) were added in duplicate wells. After 4 days of culture the cells were har-2.7. Statistical analysis
The two  sided paired Student’s t-test and ANOVA analyses were used to com-
pare the data. In all cases the data had a normal distribution as determined by the
Kolmogorov–Smirnov test. p-Values <0.05 were considered signiﬁcant.
ia Res
3
3
T
a
f
i
n
b
w
e
a
a
e
T
t
i
t
3
C
g
u
p
t
(
o
1
t
d
a
3
T
M
P
d
w
s
H
p
t
I
s
a
t
s
s
w
t
n
3
C
t
f
e
CH.J. Bontkes et al. / Leukem
. Results
.1. Aza inhibits proliferation but induces activation of CD4pos
-cells in vitro
First a dose response experiment examining T-cell proliferation
nd FoxP3 expression was performed to establish the optimal dose
or Aza. In this experimental setting, CD4pos T-cell proliferation
nduced by CD3 triggering was inhibited in a dose dependent man-
er (Fig. 1a). The overall proportion of CD25hiFoxP3hi was  increased
y Aza at a concentration of 1 M (Figs. 1b, c and 4a). This dose
as previously also shown to be non-toxic and to induce FoxP3
xpression in human CD4posCD25neg T-cells [18,19]. During culture,
 FoxP3dim and a FoxP3hi population emerged in both the vehicle
s well as the Aza cultures (Fig. 1c). The FoxP3hi population also
xpresses relatively high levels of CD25, suggesting that these are
reg, while the FoxP3dimCD25pos are likely to be activated conven-
ional T-cells (Tconv) [23]. The overall increase in CD25 expression
s also suggestive for an increased activation state upon culture in
he presence of Aza (p < 0.002; Fig. 1d).
.2. In vivo Aza treatment does not affect relative or absolute
D3posCD4pos T-cell numbers
The frequency of circulating CD4pos T-cell subsets was investi-
ated in patients with int-2 and high risk MDS, CMML  and AML
ndergoing Aza treatment. Blood samples were obtained from 9
atients before the start of treatment, 15 days after the start of
reatment and for 6 patients at the end of the third cycle as well
Table 1). No changes in absolute number of CD3pos T-cells (mean
f 1.9; 1.7; 1.5 × 109/l), CD3posCD4pos T-cells (mean of 1.1; 1.0;
.0 × 109/l), or in the proportion of CD3posCD4pos T-cells relative
o CD45hi lymphocytes (mean of 59.7, 60.8, 64.5%) were observed
uring treatment (all before, 15 days after the start of treatment
nd after 3 cycles, respectively).
.3. Aza affects in vivo and in vitro cytokine production
The capacity of both Aza-cultured healthy donor-derived CD4pos
-cells (Fig. 2a, c and e) and of CD4pos T-cells from Aza treated
DS  patients (Fig. 2b, d and f) to produce cytokines upon
MA/ionomycin stimulation was investigated (representative FACS
otplots are shown in Supplementary Fig. 2). The number of IFN as
ell as TNF producing cells was increased by Aza, again demon-
trating that Aza enhances in vitro T-cell activation (Fig. 2a and c).
owever, in vivo, no signiﬁcant change was observed in the pro-
ortion of IFN or TNF producing cells in MDS  patients after Aza
reatment (Fig. 2b and d). IL-17 producing cells can be divided into
FN negative TH17 and IFN co-producing TH17-1 cells. It has been
uggested that these cells have a differential origin and function
nd were therefore analyzed separately. No signiﬁcant changes in
he proportion of IL-17posIFNpos TH17-1 cells were observed (not
hown), however the proportion of IL-17posIFNneg TH17 cells was
igniﬁcantly reduced by Aza both in the in vitro culture system as
ell as in vivo in Aza treated MDS  patients (Fig. 2e and f), leading
o an increased IL-17posIFNpos/IL-17posIFNneg ratio (p < 0.04 data
ot shown).
.4. Aza differentially affects cytokine production by CD25neg and
D25pos cells in vitro
While the number of IFN producing CD4pos T-cells was consis-
ently up-regulated by Aza in all donors upon in vitro stimulation,
or TNF this was only the case in 7/10 donors. We  hypoth-
sized that Aza differentially affected the activation of resting
D4posCD25neg and previously activated CD4posCD25dim T-cellsearch 36 (2012) 921– 930 923
and that differences in activated T-cell frequencies among the
different donors may  have caused this variation in TNF pro-
ducing cells. We  therefore sorted the CD4pos T-cell into recently
activated CD25dim cells and resting CD25neg cells and analyzed
whether Aza has differential effects on resting versus recently
activated CD4pos T-cells. Co-staining with CD45RO and CD27
showed that effector memory (CD45ROposCD27neg) and central
memory (CD45ROposCD27pos) CD4pos T-cells are CD25dim and
that naïve CD45ROnegCD27posCD4pos T-cells are predominantly
CD25neg (Fig. 3a).
The number of IFN producing cells was  up-regulated by Aza
both among CD25neg as well as CD25dim cells in all donors (Fig. 3b),
while TNF production was  only affected in the CD25dim popula-
tion, where it was up-regulated in all donors (Fig. 3c). In contrast,
the proportion of IL-17 producing cells, although very low, was
consistently increased under the inﬂuence of Aza in the CD25neg
population (Fig. 3d). These data suggest that differential epigenetic
regulation by DNA methylation plays a role in IL-17 and TNF pro-
duction by recently activated CD25dim and resting CD25neg CD4pos
T-cells.
3.5. Aza affects in vitro and in vivo Treg development
In vitro Aza treatment signiﬁcantly increased the conversion
into CD25hiFoxP3hi cells from the total population of CD4pos T-
cells (p < 0.0002; Fig. 4a), and from isolated CD4posCD25neg as
well as CD4posCD25dim cells (p < 0.004, not shown). CD25hi cells
ceased to proliferate when cultured in the presence of Aza, indicat-
ing that the increase in CD25hiFoxP3hi cells among proliferating
CD4pos T-cells in the presence of Aza is due to conversion of
conventional CD25neg/dim cells, rather than due to proliferation
of CD25hiFoxP3pos cells (not shown). In vivo there was  a trend
toward an increase in the proportion of FoxP3pos Treg within the
CD3posCD4pos T-cell population on day 15 of the ﬁrst cycle but
the number of FoxP3pos Treg was  reduced again to levels before
treatment at the end of the third cycle (Fig. 4b).
It is known from literature that particularly the balance of effec-
tor T-cells (Teff) and Treg determines whether there is immunity or
immune suppression [24,25]. Furthermore, an increased TH17:Treg
ratio in low risk MDS  as compared to high risk MDS  has been cor-
related to increased bone marrow apoptosis [12]. We,  therefore,
analyzed the effect of Aza treatment on the TH17:Treg ratio as
well as on the IFN:Treg and TNF:Treg ratio’s. Due to the (ini-
tial) increase in Treg and the decline in IL-17 producing T-cells,
the TH17:Treg ratio is signiﬁcantly reduced in the in vitro cultures
(p < 0.05; Fig. 4c) as well as in vivo 15 days after the start of treat-
ment (p < 0.02; Fig. 4d). In contrast to TH17, the number of IFN
and TNF producing cells was increased in vitro by Aza, neverthe-
less, due to the strong concomitant increase in Treg numbers, the
IFN:Treg and TNF:Treg ratio’s were also signiﬁcantly reduced
when the cells were treated with Aza (p < 0.03; not shown).
To study whether the in vitro change in cytokine production was
due to a change in expression of transcription factors related to IFN
and IL-17; T-bet and RORT respectively, QRT-PCR was performed
on CD25neg cells on day 6. No changes in T-bet and RORT expres-
sion were observed, while FoxP3 mRNA expression was enhanced
with borderline signiﬁcance (Fig. 4e). These data suggest that Aza
affects the methylation status of the cytokine promoters, allowing
greater access to these transcription factors rather than affecting
cytokine expression through modulation of transcription factor
expression.3.6. Aza induced CD25hiFoxP3pos cells have regulatory function
In humans FoxP3 is not only expressed by Treg but is also up-
regulated in activated T-cells. As CD25 expression as well as the
924 H.J. Bontkes et al. / Leukemia Research 36 (2012) 921– 930
Fig. 1. In vitro effect of Aza on proliferation, FoxP3 and CD25 expression of CD4pos T-cells. Proliferation and activation of isolated CD4pos T-cells was induced by CD3 cross-
linking.  Vehicle or indicated concentrations of Aza were added at the start of the culture and on two consecutive days of culture, cells were analyzed on day 6. (a) Increasing
concentrations of Aza inhibit CD4pos T-cell proliferation (n = 4). (b) FoxP3 expression is increased at 1 M (n = 4). (c) Example of ﬂowcytrometric analysis of CD25 and
i  Aza tr
t MF  = m
p
p
t
r
f
antracellular FoxP3 staining of pre-culture CD4pos T-cells (ex vivo), vehicle (veh) and
he  numbers represent the percentage of cells in the quadrant. (d) CD25 expression (
 < 0.002; 2-sided paired Student’s t-test.
roportion of IFN and TNF producing cells is increased by Aza,
he increase in FoxP3 expression may  be a sign of T-cell activation
ather than a true conversion of Tconv into Treg. To study this in
urther detail we performed FoxP3 double stainings with both IFN
nd TNF (representative dotplots are shown in Supplementary Fig.eated cells. Cells in the upper right quadrant represent cells with a Treg phenotype;
ean ﬂuorescence intensity) is signiﬁcantly up-regulated by Aza treatment (n = 11);
3). Indeed double positive cells could be detected but the propor-
tion of FoxP3 single positive cells was  signiﬁcantly increased by Aza
(p < 0.001, Fig. 5a), indicating that these may  indeed be Treg rather
than activated Tconv. To establish regulatory function, vehicle and
Aza treated cells were sorted into CD25hi and CD25dim/neg cells as
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Fig. 2. In vitro and in vivo effect of Aza on IFN, TNF and IL-17 production by CD4pos T-cells. (a, c, and e) Proliferation and activation of isolated CD4pos T-cells was induced
by  CD3 cross-linking. Vehicle or 1 M of Aza was added at the start of the culture and on two  consecutive days of culture, cells harvested on day 6 were analyzed for IFN
(n  = 12) TNF (n = 10) and IL-17 (n = 12). (b, d, and f) ex vixo analysis of CD3posCD4pos cells of MDS  patients before treatment (n = 8), on day 15 of the ﬁrst cycle (n = 8) and after
3  cycles (n = 6). Cytokine production was analyzed after 16 h stimulation with PMA/ionomycin in the presence of Brefeldin A. (a and b) the proportion of IFN producing
c  IL-17p
a
t
f
a
C
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C
cells;  (c and d) the proportion of TNF producing cells; (e and f) the proportion of
nd  2-sided ANOVA (f).
o enrich the CD25hi population for FoxP3hi cells (Fig. 5b). These
our populations as well as uncultured CD25neg control cells were
dded to autologous CD4pos T-cells and their capacity to inhibit
D3-triggered proliferation was analyzed. Indeed CD25hi cells iso-
ated from Aza treated cultures were highly capable of inhibiting
D4pos T-cell proliferation whereas the CD25hi isolated from vehi-
le treated cell inhibited proliferation to a much lesser extendosIFNneg TH17 cells. p values are from 2-sided paired Student’s t-test (a, c, and e)
(Fig. 5c). These data show that Aza indeed facilitates the conversion
of Tconv into FoxP3pos Treg in this experimental setting.4. Discussion
Immune evasion characterized by increased numbers of
FoxP3pos Treg [14] as well as abnormal production of inﬂammatory
926 H.J. Bontkes et al. / Leukemia Research 36 (2012) 921– 930
Fig. 3. In vitro effect of Aza on IFN, TNF and IL-17 production by CD4posCD25neg and CD4posCD25dim T-cells. (a) CD45ROposCD27neg effector memory, CD45ROposCD27pos
central memory and CD45ROnegCD27pos naïve CD4+ T-cells were gated and the level of CD25 expression is shown. Open histograms: isotype control; closed gray histograms:
CD25. (b–d) Proliferation and activation of isolated CD4posCD25neg and CD4posCD25dim T-cells was  induced by CD3 cross-linking. Vehicle or 1 M of Aza was added at the
start  of the culture and on two consecutive days of culture, cells were harvested on day 6. The frequency of (b) IFN (n = 7), (c) TNF (n = 6) and (d) IL-17 (n = 7) producing
cells  after 16 h stimulation with PMA/ionomycin is shown. Left panels: results from CD25neg cultured cells; right panels: results from CD25dim cultured cells. p-Values are
from  2-sided paired Student’s t-tests.
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Fig. 4. In vitro and in vivo effect of Aza on the development of Treg. (a and c) Proliferation and activation of isolated CD4pos T-cells or (e) CD4posCD25neg was induced by CD3
cross-linking. Vehicle or 1 M of Aza was added at the start of the culture and on two  consecutive days of culture, cells were harvested on day 6. Treg were deﬁned as (a)
CD25hiFoxP3hi in Aza cultured cells (n = 12) or (b) as CD3posCD4posCD127lo/negFoxP3pos in PBMC of Aza treated MDS  patients before treatment (n = 9), on day 15 of the ﬁrst
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aycle  (n = 9) and after 3 cycles (n = 6). TH17:Treg ratio among (c) in vitro cultured cell
he  ﬁrst cycle (n = 8) and after 3 cycles (n = 6). (e) Expression of Tbet (n = 5; p > 0.10)
n  CD4posCD25neg cells cultured in vitro with Aza. p-Values are from 2-sided paired 
ytokines may  be related to the outgrowth of (transformed) blasts
n high risk MDS  cases. Many genes are regulated by epigenetics,
mong them are genes involved in the regulation of the immune
esponse, such as FoxP3. Previous in vitro studies have shown that
ethylation of the FoxP3 promoter plays an important role in the
egulation of FoxP3 expression and demonstrated an up-regulation
f FoxP3 expression in CD25negCD4pos T-cells upon stimulation in
he presence of Aza or decitabine [15,18,21]).  Here we conﬁrm
hese results and demonstrate that during T-cell activation Aza
ncreases FoxP3 mRNA and protein expression from both CD25dim
nd CD25negCD4pos T-cells, while Aza did not affect proliferation of12) and (d) PBMC of Aza treated MDS  patients before treatment (n = 8), on day 15 of
T (n = 4; p > 0.10) and FoxP3 (n = 5; p < 0.08) transcripts (relative to the HPRT gene)
nt’s t-tests.
isolated CD25hiCD4pos T-cells which are highly enriched for natu-
ral Treg. FoxP3 expression in humans, particular in cultured T-cells,
can also be a sign of T-cell activation rather than a sign of Treg
conversion [23]. Indeed, cytokine expressing FoxP3 positive cells
were observed both in control as well as Aza cultures as was  pre-
viously shown by Nagar et al. [21]. However we show here that at
least a proportion of the converted FoxP3 did not express IFN or
TNF and that Aza cultured CD25hi cells had a stronger capacity to
inhibit autologous CD4pos T-cell proliferation as compared to vehi-
cle cultured cells. These data show that during T-cell activation Aza
induces conversion of Tconv rather than affecting the proliferation
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Fig. 5. Analysis of regulatory function of FoxP3pos cells. Proliferation and activation of isolated CD4pos T-cells was induced by CD3 cross-linking. Vehicle or 1 M of Aza
was  added at the start of the culture and on two consecutive days of culture, cells were harvested on day 6. (a) Cells were stimulated with PMA/ionomycin in the presence
of  Brefeldin A and analyzed after 16 h for the presence of IFNposFoxP3neg (left panel) and TNFposFoxP3neg (right panel) cells (n = 7). p-Values are from 2-sided paired
Student’s t-tests. (b) FoxP3 analysis of sorted CD25neg/dim (top panels) and CD25hi (bottom panels) cells of CD4pos T-cell cultured in the presence of vehicle (left panels) or Aza
(right  panels). Numbers in upper right quadrant are the percentage of CD25hiFoxP3pos Treg. (c) Treg assay: untreated CD4posCD25neg control cells (Untr CD25neg), vehicle
treated CD25neg/dim (veh CD25neg) and CD25hi (veh CD25pos) cells and Aza treated CD25neg/dim (aza CD25neg) and CD25hi (aza CD25pos) cells were added to autologous
CD3  stimulated CD4pos T-cells at a ratio of 2:1 and 1:1 and proliferation was  measured by CFSE dilution. The proliferation inhibition by the different Treg populations is
plotted.
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f natural Treg. To investigate whether Aza also induces an increase
n Treg frequencies in vivo, we analyzed Treg frequencies in nine
igh risk MDS  patients who were treated with Aza. A trend toward
ncreased Treg was observed on day 15 of the ﬁrst cycle, but Treg
umbers were reduced again to levels before treatment at the end
f the third cycle. The lack of a sustained increase in FoxP3 positive
ells may  be related to the lack in clinical response as only 2 patients
ad a clinical response. However, only one of these two patients was
nalyzed after 3 cycles and also did not show a sustained increase in
oxP3 positive cells (Supplementary Fig. 4A). Intrinsic differences
etween CD4pos T-cells derived from healthy donors and high-risk
DS  patients are unlikely to be involved in this effect since CD4pos
-cells isolated from Aza naive high-risk MDS  patients stimulated
n vitro with Aza showed a comparable increase in FoxP3pos Treg
s the healthy donor derived CD4pos T-cells (data not shown). The
ack of a signiﬁcant sustained increase in Treg in vivo may  rather
e due to the dose of Aza the T-cells are exposed to in vivo. As we
emonstrate here, the window of Aza levels at which it induces
oxP3 in CD4pos T-cells is quite narrow; at 0.1 M the drug has
o effect, while at 10 M the drug is toxic (see Fig. 1b). Further-
ore, the in vitro increase in FoxP3 expression was observed after a
trong stimulus by immobilized anti-CD3 while T-cell activation in
he peripheral blood, particularly of high-risk MDS  patients, may  be
ess evident. Unfortunately the material obtained was  not sufﬁcient
o test for functional Treg activity or to analyze the methylation sta-
us of the Treg speciﬁc demetylated region (TSDR) [26] to conﬁrm
hat the CD3posCD4posCD127lo/neg cells are indeed functional Treg.
In cancer, both positive and negative associations with IL-17
roducing cells have been described [27–30].  This may  be related
o their microenvironment dependent plasticity and capacity to co-
roduce other inﬂammatory cytokines such as IFN [31,32]. CD4pos
-cells expressing IL-17 with (TH17-1) or without IFN (TH17), are
ound in inﬂamed gut area’s of Crohn’s disease patients [33] indicat-
ng that they contribute to pathogenic chronic inﬂammation. The
elative contribution of TH17-1 and TH17 in inﬂammatory disorders
nd cancer is still unclear. We  have found that the small fraction of
H17-1 cells is not signiﬁcantly affected by Aza while we  show a sig-
iﬁcant reduction in TH17 by Aza both in vitro and in vivo, whereas
he overall frequency of total CD4pos IL-17 producing cells was  not
igniﬁcantly affected. These data suggest that the development of
hese two subsets is differentially regulated. Recent data showing
hat TGF is crucial for the development of IL-17posIFNneg TH17
hile IL-1 is important for the development of IL-17posIFNpos
H17-1 cells also suggest this [34]. In addition IL-6 plays a role in the
ifferentiation and proliferation of TH17. As TGF and IL-6 are pro-
uced by (among other cells) TH2 cells, these cytokines may indeed
e inhibited by Aza [35] as it induces a predominant TH1 response
[36] and this paper). Larger in vivo studies relating TH17 and TH17-
 subsets frequencies with clinical responses to (Aza) treatment
ay  shed more light on the relevance of these subsets. Similar to
olid tumors, opposing observations regarding TH17 in MDS  have
een described. While TH17 were increased in the peripheral blood
12], TH17 were dysfunctional and reduced in frequency in the bone
arrow of low-risk patients but increased in the bone marrow of
igh risk patients [13], suggesting a detrimental effect of IL-17 in
he tumor microenvironment. Unfortunately we  did not analyze
D4 T-cell polarization in the bone marrow of the high risk patients
reated with Aza in the present study and whether Aza affects TH17
n the bone marrow remains to be investigated.
An increased TH17:Treg ratio in the peripheral blood of low risk
DS  patients as compared to high risk MDS  patients has been cor-
elated to increased bone marrow apoptosis [12]. We  therefore
nalyzed the effect of Aza treatment on the TH17:Treg ratio. In vitro
his ratio is signiﬁcantly reduced and due to the initial increase
n Treg and the decline in IL-17 producing T-cells, the TH17:Treg
atio is signiﬁcantly reduced in vivo 15 days after the start ofearch 36 (2012) 921– 930 929
treatment. When analyzing the change in Treg and TH17 fre-
quencies in individual patients no or a relatively modest immune
modulation was observed in both patients with stable disease
(showing a slight decrease in Treg, rather than an increase) and
a more or less stable TH17:Treg ratio on day 15. On the other hand
both responding patients showed comparable immune modulation
by Aza treatment to the four progressive patients (Supplementary
Fig. 4). Studies with extended patient groups will have to be per-
formed to elucidate whether a lack of immune modulation by Aza
is related to better clinical responses.
Within the predominantly naïve CD25neg T-cell pool the pro-
portion of IL-17 producing cells was signiﬁcantly enhanced in the
presence of Aza. In contrast, when the total CD4pos T-cell pool was
activated in the presence of Aza the number of TH17 was signiﬁ-
cantly reduced, suggesting that Aza facilitated the development of
TH17 from naïve CD4pos T-cells but reduced the differentiation of
TH17 from the memory pool, particularly in the presence of Treg
(see Figs. 2a and 3d). It has been shown that Treg can differentiate
into TH17 and vice versa [37,38],  our results suggest that Aza may
facilitate the differentiation of Treg from TH17, however studies
with isolated populations are needed to corroborate this.
Conﬂicting results regarding the effects of Aza on TNF and
IFN production have been reported, Sánchez-Abarca et al. demon-
strated a signiﬁcant decrease in production by anti-CD3 stimulated
lymphocytes early (on day 2) after stimulation in the presence of
Aza [18], in contrast, Yano et al. have reported a TH2 to TH1 conver-
sion under the inﬂuence of Aza [16] and Nader et al. demonstrated
an increase in TNF and IFN production by Aza. In accordance
with the latter studies we observed a signiﬁcant increase in IFN
producing cells after in vitro stimulation in the presence of Aza
of both healthy donor and high-risk MDS  derived CD4pos T-cells
(not shown). TNF production was  only signiﬁcantly increased in
recently activated T-cells. However, we  observed no signiﬁcant
changes in the proportion of TNF or IFN producing cells after Aza
treatment in vivo. Why  the effect on IFN and TNF producing cells
is lacking in vivo is not clear, but it may  also be due to maximum
plasma levels, a lack of general T-cell activation or effects of Aza on
other cells, e.g. antigen presenting cells, which were not taken into
account in the in vitro studies. Together with our results showing
no change in Tbet and RoRT expression upon Aza treatment, these
data suggest that the IL-17 and TNF promoters are differentially
methylated in recently activated and resting T-cells, and that Aza
may  enhance primary IL-17 responses, while in the case of TNF,
pre-existing responses will predominantly be affected.
In conclusion, the inhibition of TH17 cells as well as increased
numbers of Treg upon Aza treatment in vitro and to a somewhat
lesser extend in vivo indicate a predominant effect of Aza on the
TH17-Treg axis. In this small group no relation with this effect
to clinical response was apparent and larger studies are needed
to establish a relation with clinical responses. It is clear however
that next to its cytotoxic effects, Aza has clear immune modulatory
effects which should be taken into account in clinical practice.
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